Gyre Therapeutics (GYRE) EBITDA Margin (QoQ) (2010 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) EBITDA Margin (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -781.00 |
| Mar 31, 2026 | -4,186.00 |
| Dec 31, 2025 | -2,234.00 |
| Sep 30, 2025 | 3,019.00 |
| Jun 30, 2025 | -1,784.00 |
| Mar 31, 2025 | 792.00 |
| Dec 31, 2024 | -1,422.00 |
| Sep 30, 2024 | 395.00 |
| Jun 30, 2024 | -1,704.00 |
| Mar 31, 2024 | 36,723.00 |
| Dec 31, 2023 | -37,736.00 |
| Sep 30, 2023 | 2,288.00 |
| Jun 30, 2023 | -977.00 |
| Mar 31, 2023 | 4,886.00 |
| Mar 31, 2022 | -101,901.00 |
| Dec 31, 2021 | 26,489.00 |
| Sep 30, 2021 | 66,180.00 |
| Jun 30, 2021 | -22,967.00 |
| Mar 31, 2021 | -60,184.00 |
| Dec 31, 2020 | 87,524.00 |